Connect with us

Cannabis

Is Cannabinol Compound Good for You?

Published

on

cannabinol compound

Cannabinol compound is a new derivative in cannabis, a product made as a result of degradation of tetra hydra cannabidiol. It has many potential benefits, and sound sleep is one of the many benefits of this compound.

The cannabis plant does not produce the product in ample quantities. However, on exposure to sunlight and heat, tetra hydra cannabidiol degenerates itself into cannabinol. The scientific process of the degradation of tetra hydra cannabidiol is oxidation as the degradation takes place in the presence of oxygen.

Why does this compound have a bad reputation?

As cannabinol or CBN has a connection with degradation which results mostly of old cannabis, there is a bad reputation built for the compound.

Scientists found this compound for the first time in their scientific exploration of a 2700 years old Chinese tomb. There they found the preserved cannabis and hence the degraded compound in it.

It has astonishing similarities with tetra hydra cannabidiol (THC)

It has a similar molecular structure to its predecessor, tetra hydra cannabidiol. Even THC itself has the compound in its name. Scientists can also make it from a process of decarboxylation. The process occurs on heating cannabis. In addition to that, the process also converts tetra hydro cannabinolic acid and cannabidiolic acid into THC and cannabidiol. These acids are present in minute quantities in cannabis.

Cannabinol compound is present in very minute quantities in cannabis. In addition, the percentage of it in an average cannabis plant is less than one percent. It is quite less in comparison to the more prevalent THC, which is present about 15 to 20 percent in the plant.

There are no strains of cannabis species which are rich in cannabinol yet. It becomes prominent only upon degradation and vaporization. There is a possibility of distilling cannabinol for concentrating it up to 60 percent. It is the same procedure that people do for extracting hemp seed oils.

Is the compound psychoactive like its parent compound, tetra hydra cannabidiol?

The product is slightly psychoactive, however, less in comparison to tetra hydra cannabidiol. Moreover, it is because it reacts with the CB1 receptors in the endocannabinoid system in humans.

These receptors are responsible for the initiation of psychoactive effects of cannabis if it contains psychoactive compounds. Cannabinol compound has almost no affinity to bind itself with these receptors. Furthermore, it is because it does not fit into the receptors due to its structural configuration.

Old studies have shown CBN to be unable to cause psychoactive effects in humans. A study in 1973 concluded that there were no obvious mental and physical anomalies present in people who used CBN. They did the study on six males.

Moreover, seven years later, another study found that CBN had no negative effect on the cognitive functions of the people consuming them. There was no change in motor functions as well.

People who are more sensitive to THC will not feel the same sensitivity on exposure to the CBN. However, some scientists suggest that this compound might amplify the psychoactive effects of the THC.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis

Factors That Could Potentially Affect Your Cannabis High

Published

on

Every smoker has their own favorite strain. However, a lot of factors may affect the personal preferences of cannabis smokers. The smoker can empower himself to have better experiences with a variety of strains, by an understanding of the factors that can affect his high, and then select the one that works best for himself. These are the factors that affect your cannabis high.

Set and setting

The cannabis smoker’s environment is essential when talking about his cannabis high. A difference in scenarios tends to affect your high, and hence consideration of your comfort level is important. Being aware of our surroundings will help you figure out what set and setting work best for you, and eventually lead to more enjoyable cannabis high.

Delivery method

Cannabis has various delivery methods – smoking, vaping and edibles, however, each has its own variable. Your body is designed to differently process the cannabis from each method. Furthermore, the amount of cannabis consumed varies with each method, along with the duration of a high – which is reportedly longer, with stronger effects, with edibles.

The quality and length of your cannabis high are subsequently affected by all of these factors. However, limitations with each method are important to recognize.

Dose

A new strain, or cannabis consumption with edibles, can lead to tricky factors regarding dosage which is why starting at a low dose is essential and recommended. The most important factor that affects the smoker’s high could be the dosage. Consequently, finding your sweet spot with the perfect preferred dosage can give you the best possible cannabis experience.

Cannabinoid profile

This could be one of the most accessible ways to determine the effects of a high on an individual. While some may enjoy the effects of THC, others may find the effects too stimulating or have bad reactions such as anxiety. Considering other cannabinoids as well – such as CBD and more, cannabinoid profiles hold diversity from strain to strain. Experimentation is required to see how each cannabinoid makes you feel. This will give you the power of altering the composition of a strain to give you the type of high you want. However, other factors such as the CBD: THC ratio of the strain can also affect your high.

Terpenes

The scents and tastes in strains are given by terpenes. While their role in cannabis high, require further research, some anecdotal evidence has seemed to support the validity of its role. The potential stress-relieving effects of limonene and the relaxed mood-enhancing effects of linalool could be an example. Meanwhile,  linalool is also what gives lavender its scent, and lavender has shown proven relaxing effects.

Age

A link was found between age and effects of cannabis in a 2007 study conducted on rats. Adolescent rats showed higher tolerance levels for the effects of weed compared to adult rats, which showed increasing signs of stress, anxiety, and repressed movement. Further research on age is still necessary, but re-evaluation of the amount and kind of cannabis you consume is recommended if the last time you smoked was as a teenager.

Tolerance                                                                          

Every person has an individualized cannabis tolerance level. Tolerance is affected by the aforementioned age and other factors that include the frequency of consumption, body chemistry, and the duration of the time period that you have been smoking. To limit consumption especially when consuming cannabis with other people with different tolerances, it is essential to know one’s own personal tolerance.

In conclusion, only the cannabis consumer can determine his own tolerance. Consequently, it helps the consumer hold power over the type of cannabis high that he wants.

Continue Reading

Cannabis

DEA to Review Applications to Grow Cannabis for Research, After 4 Years Delay

Published

on

The Drug Enforcement Administration (DEA) has finally announced, after nearly 4 years, that 37 applications to grow cannabis for medical research, will be evaluated, while proposing new rules for the prospective growers, thus outlining how the cannabis-growing program would work.

According to one of the applicants, CEO of the Biopharmaceutical Research Company, George Hodgin, this framework’s release is probably the biggest, the most meaningful, and material progress that has been made for decades, in the federal cannabis policy. He further adds that this will further open a path for the traditional drug development in the United States, while researchers can conduct trials and seek approval for marijuana-based therapies, from the Food and Drug Administration (FDA).

However, everyone didn’t share the optimism of Hodgin. According to Shane Pennington, an attorney at Yetter Coleman LLP – a Houston law firm representing one of the applicants, the Scottsdale Research Institute, it may take years for Federal rulemaking due to the involvement of soliciting and responding to public comments, especially potential litigation over the decision.

Currently, only the University of Mississippi has grown cannabis, which can be legally used for research in the United States, under a contract with the National Institute on Drug Abuse (NIDA). However, there has been growing interest in the potential medical benefits of cannabis, along with the increasing number of Americans using cannabis in states where the drug is legalized. Consequently, researchers are frustrated due to the limitation of the single source.

DEA announced the consideration of applications in August 2016, from other growers. Universities, research institutes, biotech startups, and companies that produced cannabis in states where it was legalized, were all included in the list of prospective growers. However, a few months later, the election of President Donald Trump followed, and a longtime marijuana critic, Jeff Sessions was appointed as attorney general, putting him indirectly in charge of DEA. According to Hodgin, the applicants waited for 3 years, with multiple attempts involved, at outreach through Congress and directly.

The delays frustrating SRI, caused a lawsuit against DEA to be filed in June 2019, aiming to compel it to evaluate and respond to the applications. Only after proposing rules for administering the whole program, was DEA ready to evaluate the pending applications. Reactions from applicants were mixed, ranging from cautiously optimistic to interpreting the move as a stall tactic.

DEA finally released the proposed rules last week. The agency noted that 595 researchers were registered to conduct cannabis studies – increasing from 371 researchers in 2017 and that the production quota for cannabis was increased from 472 to 3200 kilograms during the same time period.

According to Sisley and her legal time, the stipulation is seen as an unnecessary roadblock. She further added, asking why cannabis should be any different when DEA has a mechanism for allowing manufacture and distribution of other tightly regulated drugs for clinical research, that include MDMA, LSD, and psilocybin – all of which are studied as possible treatments for medical conditions such as PTSD and depression.

The new rules may require that growers should have broken no federal laws. If enforced, this may immediately eliminate several applicants and companies that already continue the production or distribution of cannabis in states where the drug is legalized, as growing and selling, or even the possession of cannabis is still a violation of federal law even in cannabis-legalized states.

According to Sisley, SRI complies with federal law and has not yet grown any cannabis, although the requirement will eliminate experienced growers who are responsible for the production of high-quality cannabis (who are essentially ideal participants)

Other countries including Canada and Australia, have licensed growers for research cannabis that are not legalized to take possession of the drug.

Continue Reading

Cannabis

New Zealand Launches Medical Cannabis Scheme for Improved Consumer Access

Published

on

Part of the government’s Ministry of Health, New Zealand’s Medical Cannabis Agency launched its new Medical Cannabis Scheme on April 1, 2020, to improve patients’ access to quality medical cannabis products.

The Ministry of Health developed the scheme for the allowance of the domestic commercial cultivation, manufacture, and distribution of medical cannabis. Furthermore, the quality and licensing requirements are also set out and the scheme is further aligned with the commencement of the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. Local cultivation and manufacture of medicinal cannabis products will be allowed by new regulations, potentially easing the pain of thousands of people, according to the Minister of Health, Dr. David Clark. Issuance of the first medicinal cannabis licenses is expected by mid-2020.

As of the current situation in New Zealand, prescriptions for cannabis products that are sourced from other countries can be filled y medical cannabis patients. However, this can prove to be extremely costly for the patient. Hence, this scheme aims to be cost-effective by bringing down the cost for patients through the availability of locally produced medicine.

Dried products, and a variety of tablets and liquids, are included in the list of the medical cannabis products that have been permitted under the scheme. However, cannabis products that can be smoked are not allowed. Furthermore, cannabis products can be acquired by patients, only from a licensed doctor.

The scheme was announced in December. According to Dr. Clark, watching a loved one struggle with chronic pain and/or particularly near the end of their lives is an experience that many New Zealanders had to go through. He further added how medical cannabis products are expected to potentially make a real difference in the quality of people’s lives. He further explained how the regulations will put the infrastructure in order, thus allowing New Zealanders to locally grow, manufacture, and provide quality medicinal cannabis products, which are intended to help and make a difference in the lives of people living in pain and the people who are nearing the end of their lives.

Before April 1, 2020, approval was needed from the Ministry of Health, by licensed medical practitioners, to be able to prescribe certain products on a case-by-case basis. Removal of these requirements will be made under the new regulations, providing more ease to licensed medical practitioners to prescribe medicines to their patients.

Expecting the issuance of the first license by the middle of this year, the agency has started taking applications for licenses. Potential applicants are required to already have a secured and suitable location, along with the certainty that the facilities that been built or purchased are suitable, along with adequate security for these facilities.

The Ministry has noted that the minimum quality standards are designed to help provide doctors, the confidence in the quality and consistency of medicinal cannabis products, that they prescribe to their patients, and that the standards do not have an inclusion of an assessment of the safety or efficacy of the product.

According to Dr. Clark, over time the suffering of people will be eased by the Government’s medical cannabis scheme, by increasing the availability of a wider range of quality medicinal cannabis products. He further added that the potential of medicinal cannabis holds a huge international interest. Furthermore, the regulations necessarily mean that the New Zealand companies will now be well-placed for the manufacture of medicinal cannabis products for both, the local and international markets. He added, that considerable expertise in the market already exists with 20 licensed cannabis companies (for research) and another 238 growing industrial hemps. Dr. David Clark further added that he expects them to be potential applicants.

 

Continue Reading

Trending